Biopharma was Grifols’s largest segment in fiscal 2025, bringing in $6.49B of $7.52B (86%).
| Segments [axis] | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma | $5.01B | $5.56B | $6.14B | $6.49B | |||||||
| Bioscience | — | — | — | — | |||||||
| Diagnostic | $671.29M | $670.00M | $645.00M | $640.00M | |||||||
| Others | $250.17M | $204.00M | $208.00M | $243.00M | |||||||
| Bio Supplies | $146.08M | $160.00M | $216.00M | $154.00M | |||||||
| Hospital | — | — | — | — | |||||||
| Intersegments | -$8.95M | — | — | — | |||||||
| Total | $6.06B | $6.59B | $7.21B | $7.52B |
Grifols brought in $7.52B from its four segments in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $7.21B in fiscal 2024. Biopharma was the largest at $6.49B (86.2%), ahead of Diagnostic at $640.00M (8.5%) and Others at $243.00M (3.2%). The remaining segment, Bio Supplies, brought in $154.00M.
Compared with fiscal 2024, Others grew fastest, up 16.8% to $243.00M, while Bio Supplies fell the most, down 28.7% to $154.00M.
Haemoderivatives was Grifols’s largest revenue line in fiscal 2025, bringing in $6.49B of $7.52B (86%).
| Products and services [axis] | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Haemoderivatives | $5.01B | $5.56B | $6.14B | $6.49B | ||||||
| Transfusional Medicine | $640.60M | $648.00M | $625.00M | $623.00M | ||||||
| Others | $250.17M | $204.00M | $208.00M | $243.00M | ||||||
| Other Product | — | — | — | — | ||||||
| Bio Supplies | $146.08M | $160.00M | $216.00M | $154.00M | ||||||
| Hospital Supplies | — | — | — | — | ||||||
| Fluid Therapy & Nutrition | — | — | — | — | ||||||
| Other Diagnostic | $21.74M | $22.00M | $20.00M | $17.00M | ||||||
| Total | $6.06B | $6.59B | $7.21B | $7.52B |
Grifols brought in $7.52B from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $7.21B in fiscal 2024. Haemoderivatives was the largest at $6.49B (86.2%), ahead of Transfusional Medicine at $623.00M (8.3%) and Others at $243.00M (3.2%). The other two revenue lines brought in $171.00M combined.
Compared with fiscal 2024, Others grew fastest, up 16.8% to $243.00M, while Bio Supplies fell the most, down 28.7% to $154.00M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $6.06B to $7.52B, a compound annual growth rate of 7.5%. Haemoderivatives' share of the total rose from 82.5% to 86.2%.
Usa & Canada was Grifols’s largest region in fiscal 2025, bringing in $4.25B of $7.52B (57%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Usa & Canada | $3.86B | $3.90B | $4.09B | $4.25B | |||||||
| Rest Of The World | $1.18B | $1.44B | $1.63B | $1.66B | |||||||
| Rest Of European Union | $711.58M | $893.00M | $1.08B | $1.20B | |||||||
| Spain | $320.63M | $363.00M | $423.00M | $418.00M | |||||||
| Total | $6.06B | $6.59B | $7.21B | $7.52B |
Grifols brought in $7.52B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $7.21B in fiscal 2024. Usa & Canada was the largest at $4.25B (56.5%), ahead of Rest Of The World at $1.66B (22.0%) and Rest Of European Union at $1.20B (15.9%). The remaining region, Spain, brought in $418.00M.
Compared with fiscal 2024, Rest Of European Union grew fastest, up 11.2% to $1.20B, while Spain fell the most, down 1.2% to $418.00M. From fiscal 2022 to 2025, combined revenue from these regions grew from $6.06B to $7.52B, a compound annual growth rate of 7.5%. Usa & Canada's share of the total fell from 63.6% to 56.5%.
Grifols (GRFS) reports its revenue by segments [axis], by products and services [axis] and by geography. In fiscal 2025, Biopharma was its largest segment, bringing in $6.49B (86.2% of the total), followed by Diagnostic at $640.00M (8.5%).
Biopharma was Grifols' largest segment in fiscal 2025, bringing in $6.49B, or 86.2% of the $7.52B total across its four segments.
Haemoderivatives was Grifols' largest revenue line in fiscal 2025, bringing in $6.49B, or 86.2% of the $7.52B total across its five revenue lines.
Usa & Canada was Grifols' largest region in fiscal 2025, bringing in $4.25B, or 56.5% of the $7.52B total across its four regions.
Among Grifols' segments that make up at least 2% of revenue, Others grew fastest in fiscal 2025, up 16.8% from $208.00M to $243.00M.
Every figure comes from Grifols' annual financial filings, as reported. Each line keeps the name Grifols gives it, and years follow its fiscal calendar.
Grifols' revenue by segments [axis] goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.